AR093671A1 - Anticuerpos monoclonales contra una proteina activada c (apc) - Google Patents
Anticuerpos monoclonales contra una proteina activada c (apc)Info
- Publication number
- AR093671A1 AR093671A1 ARP130104417A ARP130104417A AR093671A1 AR 093671 A1 AR093671 A1 AR 093671A1 AR P130104417 A ARP130104417 A AR P130104417A AR P130104417 A ARP130104417 A AR P130104417A AR 093671 A1 AR093671 A1 AR 093671A1
- Authority
- AR
- Argentina
- Prior art keywords
- apc
- activated protein
- binding
- antibody
- screening
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En la presente memoria se proporcionan anticuerpos, fragmentos de anticuerpos de unión a antígenos (Fabs) y otras proteínas de andamiaje, dirigidos contra proteína C activada humana (aPC) con unión mínima a su zimógeno de Proteína C (PC). Asimismo, estas proteínas de unión a aPC podrían bloquear potencialmente la actividad anticoagulante de aPC para inducir la coagulación. En la presente memoria se describen los usos terapéuticos de estos unidores así como también los métodos de selección y cribado de anticuerpos específicos. Reivindicación 1: Un anticuerpo monoclonal aislado, en donde dicho anticuerpo se une a proteína C activada e inhibe la actividad anticoagulante pero tiene unión mínima a proteína C no activada, en donde dicho anticuerpo comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada entre el grupo que consiste en SEQ ID Nº 14, 15, 17, 18, 19, 21, 22, 23, 109, 111, 113, 115, 117 y 119.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731294P | 2012-11-29 | 2012-11-29 | |
US201361786472P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093671A1 true AR093671A1 (es) | 2015-06-17 |
Family
ID=50828462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104417A AR093671A1 (es) | 2012-11-29 | 2013-11-29 | Anticuerpos monoclonales contra una proteina activada c (apc) |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150307625A1 (es) |
EP (1) | EP2925351A4 (es) |
JP (1) | JP2016501230A (es) |
KR (1) | KR20150088869A (es) |
CN (1) | CN104812402A (es) |
AR (1) | AR093671A1 (es) |
AU (1) | AU2013352159A1 (es) |
BR (1) | BR112015012414A2 (es) |
CA (1) | CA2892750A1 (es) |
HK (1) | HK1212896A1 (es) |
IL (1) | IL238658A0 (es) |
MX (1) | MX2015006424A (es) |
RU (1) | RU2015125349A (es) |
SG (1) | SG11201503719WA (es) |
TW (1) | TW201429992A (es) |
UY (1) | UY35154A (es) |
WO (1) | WO2014085596A1 (es) |
ZA (1) | ZA201504659B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017087391A1 (en) * | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
EP3831843A1 (en) * | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
CN115611986A (zh) * | 2021-07-13 | 2023-01-17 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
CN116496394A (zh) * | 2022-01-26 | 2023-07-28 | 东莞市朋志生物科技有限公司 | 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒 |
WO2023168429A2 (en) * | 2022-03-04 | 2023-09-07 | Coagulant Therapeutics Corporation | Camelid antibodies against activated protein c and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
EP2202242A1 (en) * | 1996-04-24 | 2010-06-30 | The Regents of The University of Michigan | Inactivation resistant factor VIII related applications |
ATE464374T1 (de) * | 2000-10-02 | 2010-04-15 | Oklahoma Med Res Found | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20030203355A1 (en) * | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
JP2008515774A (ja) * | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | hK1結合タンパク質 |
WO2006067122A2 (en) * | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
CA2633956C (en) * | 2005-12-13 | 2016-12-06 | Olivia Raeber | Binding proteins specific for insulin-like growth factors and uses thereof |
US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
JP2011500843A (ja) * | 2007-10-26 | 2011-01-06 | オクラホマ・メディカル・リサーチ・ファウンデーション | 活性化プロテインcおよび不活性化プロテインcに対するモノクロナール抗体 |
GB0903151D0 (en) * | 2009-02-25 | 2009-04-08 | Bioinvent Int Ab | Antibody uses and methods |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
GB201011771D0 (en) * | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
EP2640421A4 (en) * | 2010-11-16 | 2014-05-28 | Medimmune Llc | THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES |
US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2013
- 2013-11-27 KR KR1020157017008A patent/KR20150088869A/ko not_active Application Discontinuation
- 2013-11-27 BR BR112015012414A patent/BR112015012414A2/pt not_active IP Right Cessation
- 2013-11-27 EP EP13857869.5A patent/EP2925351A4/en not_active Withdrawn
- 2013-11-27 WO PCT/US2013/072243 patent/WO2014085596A1/en active Application Filing
- 2013-11-27 AU AU2013352159A patent/AU2013352159A1/en not_active Abandoned
- 2013-11-27 RU RU2015125349A patent/RU2015125349A/ru not_active Application Discontinuation
- 2013-11-27 MX MX2015006424A patent/MX2015006424A/es unknown
- 2013-11-27 US US14/443,710 patent/US20150307625A1/en not_active Abandoned
- 2013-11-27 SG SG11201503719WA patent/SG11201503719WA/en unknown
- 2013-11-27 CA CA2892750A patent/CA2892750A1/en not_active Abandoned
- 2013-11-27 CN CN201380062159.XA patent/CN104812402A/zh active Pending
- 2013-11-27 JP JP2015545438A patent/JP2016501230A/ja active Pending
- 2013-11-28 UY UY0001035154A patent/UY35154A/es not_active Application Discontinuation
- 2013-11-28 TW TW102143366A patent/TW201429992A/zh unknown
- 2013-11-29 AR ARP130104417A patent/AR093671A1/es unknown
-
2015
- 2015-05-06 IL IL238658A patent/IL238658A0/en unknown
- 2015-06-26 ZA ZA2015/04659A patent/ZA201504659B/en unknown
-
2016
- 2016-01-27 HK HK16100878.9A patent/HK1212896A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2925351A4 (en) | 2016-08-24 |
TW201429992A (zh) | 2014-08-01 |
SG11201503719WA (en) | 2015-06-29 |
IL238658A0 (en) | 2015-06-30 |
WO2014085596A1 (en) | 2014-06-05 |
JP2016501230A (ja) | 2016-01-18 |
UY35154A (es) | 2014-06-30 |
KR20150088869A (ko) | 2015-08-03 |
CA2892750A1 (en) | 2014-06-05 |
ZA201504659B (en) | 2017-11-29 |
RU2015125349A (ru) | 2017-01-10 |
AU2013352159A1 (en) | 2015-06-04 |
HK1212896A1 (zh) | 2016-06-24 |
US20150307625A1 (en) | 2015-10-29 |
BR112015012414A2 (pt) | 2017-09-12 |
EP2925351A1 (en) | 2015-10-07 |
MX2015006424A (es) | 2015-08-14 |
CN104812402A (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
TR201910348T4 (tr) | Matriks metalloproteinaz 9 için antikorlar. | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
PE20150360A1 (es) | Agentes de union de proteina de r-espondina humana (rsp03) y usos de los mismos | |
ECSP14001260A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
EA201991546A1 (ru) | Антигенсвязывающие белки против нейропилина и способы их применения | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201170357A1 (ru) | Инженерные антитела к il-13: композиции, способы и применение | |
EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
AR093671A1 (es) | Anticuerpos monoclonales contra una proteina activada c (apc) | |
EA201690114A1 (ru) | КОНЪЮГАТ Fc ИММУНОГЛОБУЛИНА, СОХРАНЯЮЩИЙ СПОСОБНОСТЬ СВЯЗЫВАНИЯ С FcRn | |
EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения | |
UY35457A (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |